Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Lenalidomide (Revlimid®), Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Amyloidosis

NCT00564889 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT00564889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00564889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Lenalidomide (Revlimid®), Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Amyloidosis
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2007
Completion date
June 30, 2012
Enrollment
35 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma and plasma cell neoplasm